Hemangioendothelioma

WikiDoc Resources for Hemangioendothelioma
Articles
Most recent articles on Hemangioendothelioma Most cited articles on Hemangioendothelioma Review articles on Hemangioendothelioma Articles on Hemangioendothelioma in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Hemangioendothelioma Images of Hemangioendothelioma Photos of Hemangioendothelioma Podcasts & MP3s on Hemangioendothelioma Videos on Hemangioendothelioma
Evidence Based Medicine
Cochrane Collaboration on Hemangioendothelioma Bandolier on Hemangioendothelioma TRIP on Hemangioendothelioma
Clinical Trials
Ongoing Trials on Hemangioendothelioma at Clinical Trials.gov Trial results on Hemangioendothelioma Clinical Trials on Hemangioendothelioma at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Hemangioendothelioma NICE Guidance on Hemangioendothelioma NHS PRODIGY Guidance FDA on Hemangioendothelioma CDC on Hemangioendothelioma
Books
Books on Hemangioendothelioma
News
Hemangioendothelioma in the news Be alerted to news on Hemangioendothelioma News trends on Hemangioendothelioma
Commentary
Blogs on Hemangioendothelioma
Definitions
Definitions of Hemangioendothelioma
Patient Resources / Community
Patient resources on Hemangioendothelioma Discussion groups on Hemangioendothelioma Patient Handouts on Hemangioendothelioma Directions to Hospitals Treating Hemangioendothelioma Risk calculators and risk factors for Hemangioendothelioma
Healthcare Provider Resources
Symptoms of Hemangioendothelioma Causes & Risk Factors for Hemangioendothelioma Diagnostic studies for Hemangioendothelioma Treatment of Hemangioendothelioma
Continuing Medical Education (CME)
CME Programs on Hemangioendothelioma
International
Hemangioendothelioma en Espanol Hemangioendothelioma en Francais
Business
Hemangioendothelioma in the Marketplace Patents on Hemangioendothelioma
Experimental / Informatics
List of terms related to Hemangioendothelioma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Synonyms and keywords: Synonym 1; Synonym 2; Synonym 3

Historical Perspective

• Hemangioendothelioma was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
• In [year], [gene] mutations were first identified in the pathogenesis of hemangioendothelioma.
• In [year], the first [discovery] was developed by [scientist] to treat/diagnose hemangioendothelioma.

Classification

• Hemangioendothelioma may be classified according to [classification method] into [number] subtypes/groups:

• [group1]
• [group2]
• [group3]

• Other variants of hemangioendothelioma include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

• The pathogenesis of hemangioendothelioma is characterized by [feature1], [feature2], and [feature3].
• The [gene name] gene/Mutation in [gene name] has been associated with the development of hemangioendothelioma, involving the [molecular pathway] pathway.
• On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of hemangioendothelioma.
• On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of hemangioendothelioma.

Causes

• Hemangioendothelioma may be caused by either [cause1], [cause2], or [cause3].
• Hemangioendothelioma is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
• There are no established causes for hemangioendothelioma.

Differentiating hemangioendothelioma from other Diseases

• Hemangioendothelioma must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

• [Differential dx1]
• [Differential dx2]
• [Differential dx3]

Epidemiology and Demographics

• The prevalence of hemangioendothelioma is approximately [number or range] per 100,000 individuals worldwide.
• In [year], the incidence of hemangioendothelioma was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

• Patients of all age groups may develop hemangioendothelioma.

• Hemangioendothelioma is more commonly observed among patients aged [age range] years old.
• Hemangioendothelioma is more commonly observed among [elderly patients/young patients/children].

Gender

• Hemangioendothelioma affects men and women equally.

• [Gender 1] are more commonly affected with hemangioendothelioma than [gender 2].
• The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

• There is no racial predilection for hemangioendothelioma.

• Hemangioendothelioma usually affects individuals of the [race 1] race.
• [Race 2] individuals are less likely to develop hemangioendothelioma.

Risk Factors

• Common risk factors in the development of hemangioendothelioma are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

• The majority of patients with hemangioendothelioma remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with hemangioendothelioma may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of hemangioendothelioma include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with hemangioendothelioma is approximately [#%].

Diagnosis

Diagnostic Criteria

• The diagnosis of hemangioendothelioma is made when at least [number] of the following [number] diagnostic criteria are met:

• [criterion 1]
• [criterion 2]
• [criterion 3]
• [criterion 4]

Symptoms

• Hemangioendothelioma is usually asymptomatic.
• Symptoms of hemangioendothelioma may include the following:

• [symptom 1]
• [symptom 2]
• [symptom 3]
• [symptom 4]
• [symptom 5]
• [symptom 6]

Physical Examination

• Patients with hemangioendothelioma usually appear [general appearance].
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

• There are no specific laboratory findings associated with hemangioendothelioma.

• A [positive/negative] [test name] is diagnostic of hemangioendothelioma.
• An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of hemangioendothelioma.
• Other laboratory findings consistent with the diagnosis of hemangioendothelioma include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

• There are no [imaging study] findings associated with hemangioendothelioma.

• [Imaging study 1] is the imaging modality of choice for hemangioendothelioma.
• On [imaging study 1], hemangioendothelioma is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstratedemonstate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• Hemangioendothelioma may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

• There is no treatment for hemangioendothelioma; the mainstay of therapy is supportive care.

• The mainstay of therapy for hemangioendothelioma is [medical therapy 1] and [medical therapy 2].
• [Medical therapy 1] acts by [mechanism of action1].
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for hemangioendothelioma.
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of hemangioendothelioma.
• [Surgical procedure] can only be performed for patients with [disease stage] hemangioendothelioma.

Prevention

• There are no primary preventive measures available for hemangioendothelioma.

• Effective measures for the primary prevention of hemangioendothelioma include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with hemangioendothelioma are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].